Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 1:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 29.03.2024 1:00:00
NeoGenomics Inc (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
15,72 3,42 0,52 654 428
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostiNeoGenomics, Inc.
TickerNEO
Kmenové akcie:Ordinary Shares
RICNEO.O
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 2 100
Akcie v oběhu k 13.02.2024 127 610 039
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice9490 Neogenomics Way
MěstoFORT MYERS
PSČ33912
ZeměUnited States
Kontatní osobaJeffrey Sherman
Funkce kontaktní osobyChief Financial Officer
Telefon12 397 680 600
Fax17753290852
Kontatní telefon12 397 680 600

Business Summary: NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, NeoGenomics, Inc. revenues increased 16% to $591.6M. Net loss decreased 39% to $88M. Revenues reflect Clinical Services segment increase of 18% to $495.6M. Lower net loss reflects General and administrative decrease of 12% to $184.5M (expense), Research and development - Balancing decrease of 12% to $25.2M (expense).
Odvětvová klasifikace
TRBC2009Healthcare Facilities / Services
TRBC2012Medical & Diagnostic Laboratories
RBSS2004Healthcare Facilities
MGINDUSTRYHealthcare Facilities
MGSECTORHealthcare
NAICSMedical Laboratories
NAICS2007Medical Laboratories
NAICS1997Medical Laboratories
SICTesting Laboratories
SICMedical Laboratories



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, DirectorChristopher Smith6015.08.202215.08.2022
Chief Financial OfficerJeffrey Sherman5707.12.202207.12.2022
President - Enterprise OperationsMelody Harris5705.12.202205.12.2022
President - Advanced DiagnosticsVishal Sikri47
President - Clinical ServicesWarren Stone5021.11.202221.11.2022
Executive Vice President of Research and Development, Chief Scientific OfficerShashikant Kulkarni5612.01.202312.01.2023
Senior Vice President, General Manager - Oncology DiagnosticsMarcus Silva46
Chief Accounting Officer, ControllerCynthia Dieter4822.06.202022.06.2020
General Counsel, Company SecretaryAlicia Olivo3901.08.202201.08.2022